The AURORA trial's completion of patient dosing with a clean IDMC safety review is a procedural milestone, not a clinical validation. CAL101's mechanism — intravenous monoclonal antibody neutralizing extracellular S100A4 — has no approved precedent in IPF and no mechanistic peer in the available evidence base; no prior anti-S100A4 agent has cleared a Phase 3 readout in any fibrotic lung disease. [1][2] The two approved IPF standards, nintedanib and pirfenidone, are mechanistically distinct (intracellular tyrosine kinase inhibition and pleiotropic small-molecule antifibrotic, respectively) and cannot serve as mechanistic precedents — they establish only the regulatory endpoint bar: a meaningful reduction in annual FVC decline, where nintedanib's pooled Phase 3 RCT advantage over placebo was 109.9 mL/year. [3] Against that benchmark, AURORA's 161-patient Phase 2 is underpowered for a definitive efficacy signal, and topline results are not expected until Q1 2027. [4] The IPF biologic attrition record is severe: pamrevlumab (anti-CTGF, Phase 3, 372 patients) and tralokinumab (anti-IL-13, Phase 2, 409 patients) both terminated — neither shares CAL101's mechanism, so their failure does not indict S100A4, but they confirm the indication's hostility to novel biologics. [5][6] A critical unresolved design confound is whether AURORA permitted background nintedanib or pirfenidone; if not, the placebo arm may not reflect current standard of care, complicating regulatory and HTA reception. [7][8] Korean HTA denied nintedanib reimbursement for IPF on cost-effectiveness grounds despite Phase 3 validation, signaling that even a positive Phase 2 readout leaves a steep payer hill to climb for an IV biologic priced above oral generics. The sharpest risk: no efficacy data exist, and the target itself has no prior clinical proof-of-concept in humans.
AURORA is a 161-patient randomized Phase 2 with no efficacy readout until Q1 2027; the IDMC reviewed safety only. [9] No mechanistic precedent for S100A4 neutralization in IPF exists, and the trial's background-therapy design is undisclosed, limiting interpretability of the forthcoming signal.
| Indication | Idiopathic pulmonary fibrosis |
| Drug | CAL101 |
| Mechanism of Action | Monoclonal antibody, S100A4 neutralizer |
| Company | Calluna Pharma |
| Trial Phase | Phase II |
| Trial Acronym | AURORA |
| Category | Clinical Trial Event |
| Sub Category | Trial Completion / Last Patient Out |
| Therapeutic Area | Respiratory |
| Patient Population Size | 161 patients |
| Randomization Ratio | 3:2 (CAL101 vs. placebo) |
| Dosage Frequency | Monthly |
| Administration Route | Intravenous infusions |
| Treatment Duration | Six-month period |
| Primary Endpoint | Change from baseline in forced vital capacity |
| Secondary Endpoints | Circulating biomarkers, quantitative high-resolution computed tomography scans |
| Topline Results Expected | Q1 2027 |
| Recruitment Regions | European Union (EU), South Korea, Turkey, UK, US |
Calluna Pharma Completes Dosing in Phase II AURORA Trial for IPF
Calluna Pharma has announced the completion of patient dosing in its Phase II AURORA trial for CAL101, an investigational treatment for idiopathic pulmonary fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) reviewed unblinded safety data from all 161 enrolled patients and found no concerns requiring study alterations. The trial has now entered its final follow-up phase, with topline results anticipated in the first quarter of 2027. CAL101 is an intravenously delivered monoclonal antibody designed to neutralize extracellular S100A4, a protein implicated in inflammatory and fibrotic cascades.
- Calluna Pharma has successfully completed patient dosing for its Phase II AURORA trial of CAL101 in idiopathic pulmonary fibrosis (IPF). The study is now in its final follow-up phase, with the company expecting to release topline findings in the first quarter of 2027, marking a significant step towards understanding CAL101's potential.
- An Independent Data Monitoring Committee (IDMC) conducted a comprehensive review of unblinded safety data from all 161 patients participating in the trial. The committee concluded its assessment without identifying any safety concerns that would necessitate alterations to the ongoing study, reinforcing confidence in the trial's progression.
- CAL101 is an intravenously administered monoclonal antibody specifically developed to neutralize extracellular S100A4, a damage-associated molecular pattern protein. This mechanism targets upstream disease amplification by blocking persistent signaling pathways linked to abnormal fibroblast proliferation and pro-fibrotic immune activity, aiming to treat IPF without broad physiological suppression.
Addressing the Unmet Needs in Idiopathic Pulmonary Fibrosis
Despite the approval of pirfenidone and nintedanib as disease-modifying antifibrotic therapies, IPF continues to carry a high mortality burden, with a median survival of 2–3 years after diagnosis and no available treatments capable of reversing or halting the underlying fibrotic process. Both agents slow functional decline rather than restore lung function, and real-world tolerability challenges frequently compromise treatment continuity. The following points outline the principal limitations shaping current IPF management.
Tolerability-driven treatment discontinuation and dose reduction. Gastrointestinal adverse events are the predominant reason for dose reduction and cessation with both agents. In one real-world cohort, gastrointestinal intolerance led to dose reduction in 13.0% and treatment cessation in 20.4% of nintedanib-treated patients within 12 months. A separate study reported an overall discontinuation rate due to adverse events of 48.98% for nintedanib and 27.80% for pirfenidone. For pirfenidone, skin-related events (rash, photosensitivity) and gastrointestinal events (nausea) are the most commonly occurring treatment-emergent adverse events. Antifibrotic discontinuation within 3 months was identified as an independent predictor of 12-month mortality, underscoring the clinical stakes of poor tolerability.
Functional decline continues despite treatment, particularly upon discontinuation. Antifibrotic therapy slows but does not arrest FVC decline. Patients who discontinued nintedanib exhibited a statistically significant decline in FVC (% predicted) at 12 months compared to baseline (55.0 ± 13.5 vs. 70.0 ± 23.0; p = 0.035), whereas those continuing at full or reduced dose showed no significant FVC differences. In a Greek real-world cohort of pirfenidone-treated patients, 25% and 35% of patients experienced significant FVC decline (>10%) at 6 and 12 months, respectively, and median survival was 851 days.
Comorbidity burden complicates management and worsens prognosis. Patients with IPF frequently present with pulmonary hypertension, emphysema, lung cancer, gastroesophageal reflux, cardiovascular disease, diabetes mellitus, and obstructive sleep apnea. In one cohort, pulmonary hypertension was present in 49.6% of IPF patients. Comorbidities are associated with disease progression and mortality; in multivariate analysis, pulmonary hypertension carried an odds ratio of 15.39 (p = 0.02) as an independent predictor of mortality. Bacterial pneumonia and lung cancer were each independently associated with significantly higher in-hospital mortality in hospitalized IPF patients.
Acute exacerbations represent a severe, largely unmodifiable complication. Acute exacerbations (AEs) carry an in-hospital mortality rate of 50.0% and are an independent predictor of poor overall survival (HR 2.79; 95% CI 1.59–4.88; p < 0.001). The 1- and 3-year incidences of AE are 14.2% and 20.7%, respectively. Nintedanib had no significant effect on risk of mortality post-exacerbation in the INPULSIS trials, and no therapies have demonstrated a clinically significant capacity to prevent or reverse AEs. Patients with combined pulmonary fibrosis and emphysema (CPFE) face a significantly higher incidence of treatment-induced AEs (49.5% vs. 29.2%; p = 0.038) and AE-related mortality (28.0% vs. 11.8%; p = 0.045) compared to isolated IPF.
No effective therapies exist for IPF-associated pulmonary hypertension. Pulmonary hypertension related to IPF is associated with worse outcomes compared to parenchymal lung disease alone, yet no therapies are currently available to reverse or slow down the pathological process of this condition, and most clinical trials conducted to date have had no clinically significant impact on it.
Diagnostic delay limits the window for therapeutic intervention. The mean time between symptom onset and IPF diagnosis has been reported at 11.6 months. A rapid diagnostic circuit demonstrated a statistically significant reduction in time from symptom onset to diagnosis (6 vs. 22.1 months; p < 0.01) and was associated with better forced vital capacity and DLCO at diagnosis, highlighting that delayed referral pathways remain a structural barrier to timely antifibrotic initiation.
Designing the AURORA Trial for CAL101 in IPF
Several pivotal Phase 3 randomised controlled trials have established the foundational evidence base for antifibrotic therapy in IPF, each sharing FVC decline as the primary endpoint while varying in design, population, and secondary outcome structure.
| Trial / Programme | Drug(s) | Design | Population | Primary Endpoint | Key Secondary Endpoints |
|---|---|---|---|---|---|
| INPULSIS-1 & INPULSIS-2 | Nintedanib 150 mg twice daily vs. placebo | Replicate Phase 3, randomised, double-blind, multinational, 52 weeks | Patients aged ≥40 years, IPF diagnosis within 5 years, FVC ≥50% predicted, DLCO 30–79% predicted; 1,066 patients enrolled across 24 countries; randomised 3:2 (nintedanib:placebo) | Annual rate of decline in FVC | Change from baseline in SGRQ total score over 52 weeks; time to first acute exacerbation |
| FIBRONEER-IPF & FIBRONEER-ILD | Nerandomilast (phosphodiesterase-4B inhibitor) | Phase 3 randomised clinical trials (2 trials) | Patients with IPF (FIBRONEER-IPF) and other progressive pulmonary fibrosis forms (FIBRONEER-ILD) | Reduction of FVC decline over one year | Not reported |
| PROGRESSION-IPF | Pirfenidone + nintedanib combination vs. switch monotherapy vs. continuation of current monotherapy | Pragmatic, multicenter, randomised, open-label, 1:1:1 allocation | 378 patients aged ≥50 years with IPF showing progression within preceding 12 ± 6 months despite antifibrotic therapy | Slope of FVC decline over 24 weeks | Tolerability; time to treatment failure or discontinuation; hospitalization-free survival; fibrosis progression on imaging; initiation of oxygen; acute exacerbations; patient-reported outcomes; serum CA-125 (exploratory biomarker) |
| CAPACITY studies (pirfenidone) | Pirfenidone vs. placebo | Phase 3 randomised (3 trials included in comparative analyses) | Patients with IPF with mild to moderate pulmonary function impairment | FVC decline | Not reported |
| Chinese pirfenidone Phase 2 trial | Pirfenidone 1,800 mg/day + NAC 1,800 mg/day vs. placebo + NAC 1,800 mg/day | Double-blind, modified placebo-controlled, randomised, 48 weeks | 76 Chinese IPF patients with mild to moderate pulmonary function impairment (pirfenidone + NAC: n=38; placebo + NAC: n=38) | Changes in FVC, walking distance, and lowest SpO₂ during 6MWT at week 48 | Progression-free survival time |
| Pirfenidone + inhaled N-acetylcysteine trial | Pirfenidone + inhaled NAC 352.4 mg twice daily vs. pirfenidone alone | Phase 3, randomised, open-label, multicentre, 48 weeks | 81 patients with IPF (combination: n=41; pirfenidone alone: n=40) | Annual rate of decline in FVC | Serial change in DLCO and 6MWD; progression-free survival; incidence of acute exacerbation; tolerability |
| Carlumab Phase 2 | Carlumab 1, 5, or 15 mg/kg vs. placebo every 4 weeks | Phase 2, randomised, double-blind, placebo-controlled, dose-ranging | 126 patients with IPF | Rate of percentage change in FVC | Time to disease progression; absolute change in FVC; relative change in DLCO; SGRQ total score |
| SENSCIS™ | Nintedanib 150 mg twice daily vs. placebo | Phase 3, randomised, placebo-controlled | ~520 patients with SSc-ILD (≥10% lung fibrosis on HRCT), FVC ≥40% predicted, DLCO 30–89% predicted; randomised 1:1, stratified by anti-topoisomerase I antibody | Annual rate of decline in FVC (mL/year) over 52 weeks | Absolute change from baseline in modified Rodnan skin score and SGRQ at week 52 |
| INBUILD | Nintedanib vs. placebo | Phase 3, randomised | Patients with progressive fibrosing ILDs other than IPF, meeting criteria for ILD progression within 24 months (Groups A, B, C based on FVC decline and symptom/HRCT criteria) | Rate of FVC decline over 52 weeks | Not reported |
| ISABELA 1 & 2 | GLPG1690 (autotaxin inhibitor) 600 mg or 200 mg vs. placebo once daily | Phase 3, international, randomised, double-blind, placebo-controlled, parallel-group, multicentre, ≥52 weeks; 750 subjects per study randomised 1:1:1 | Patients with IPF on local standard of care | Rate of decline of FVC over 52 weeks | Week 52 composite of disease progression (≥10% absolute decline in % predicted FVC) or all-cause mortality; time to first respiratory-related hospitalisation; change from baseline in SGRQ total score at week 52 |
| BI 1819479 Phase 2 | BI 1819479 (LPA pathway inhibitor) three oral doses vs. placebo | Phase 2, randomised, double-blind, placebo-controlled, dose-finding; randomised 2:1:1:1; stratified by nintedanib/pirfenidone use | Patients aged ≥40 years with IPF, FVC ≥45% predicted, haemoglobin-corrected DLCO ≥25% predicted; treatment with nintedanib/pirfenidone permitted if stable dose ≥12 weeks | Annual rate of FVC decline (mL/year) assessed up to 52 weeks | Absolute change from baseline in FVC at week 24 |
S100A4 Neutralization: A New Frontier in IPF Treatment?
The landscape of idiopathic pulmonary fibrosis (IPF) treatment is marked by significant unmet needs, with current therapies primarily slowing disease progression rather than reversing it. Against this backdrop, Calluna Pharma's CAL101, an investigational monoclonal antibody targeting S100A4, represents a promising new therapeutic avenue. The recent announcement of completed patient dosing in its Phase II AURORA trial, coupled with a positive safety review from the Independent Data Monitoring Committee, provides a crucial de-risking signal for the program.
S100A4 is a fascinating target, implicated as a damage-associated molecular pattern that orchestrates both inflammatory and fibrotic responses. Research indicates it's secreted by alternatively activated alveolar macrophages and fibroblasts, acting as a potent activator of lung fibroblasts, promoting their proliferation, migration, and resistance to apoptosis. Furthermore, S100A4 is intertwined with several key profibrotic signaling pathways, including TGFβ, Wnt/β-catenin, FAK/ERK, and JAK/STAT. By directly neutralizing extracellular S100A4, CAL101 offers a novel, upstream mechanism of action that could differentiate it from existing treatments, which often target downstream or broader pathways.
This development carries several strategic implications:
Novel Mechanism: CAL101's direct targeting of S100A4 provides a distinct approach to disrupting the fibrotic cascade, potentially offering a more precise intervention than current multi-kinase inhibitors.
Market Positioning: A clean safety profile in Phase II could significantly enhance Calluna Pharma's competitive standing, attracting interest from potential partners or investors as the drug progresses.
Biomarker Potential: The strong correlation between S100A4 levels and IPF occurrence, particularly macrophage-derived S100A4 in the inflammatory phase, suggests S100A4 could serve as a valuable diagnostic or prognostic biomarker, aiding in patient selection or monitoring treatment response.
However, the path forward is not without its challenges. While safety is encouraging, the ultimate success hinges on demonstrating robust efficacy in a complex disease like IPF. The multifaceted role of S100A4 across numerous, sometimes redundant, profibrotic pathways means that neutralizing extracellular S100A4 might not fully address all drivers of fibrosis. Moreover, much of the foundational understanding of S100A4's role comes from bleomycin-induced animal models, and translating these findings to the heterogeneous and chronic nature of human IPF remains a significant hurdle. All eyes will now be on the topline results anticipated in Q1 2027, which will determine if CAL101 can indeed carve out a meaningful role in the evolving treatment paradigm for IPF.
Frequently Asked Questions
References
- [1] Sheikh SI, Hayes D Jr et al.. Age-Dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis. The Annals of thoracic surgery. 2017 Feb. 28341270
- [2] Koschel D, Behr J et al.. [Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 trials]. Pneumologie (Stuttgart, Germany). 2026 Jul 6. 42409049
- [3] Spagnolo P, Maher TM. The future of clinical trials in idiopathic pulmonary fibrosis. Current opinion in pulmonary medicine. 2024 Sep 1. 38963152
- [4] Capparelli I, Fernandez M et al.. Translation to Spanish and Validation of the Specific Saint George's Questionnaire for Idiopathic Pulmonary Fibrosis. Archivos de bronconeumologia. 2018 Feb. 29102341
- [5] Jenkins RG, Simpson JK et al.. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. The Lancet. Respiratory medicine. 2015 Jun. 25770676
- [6] Yu X, Li X et al.. Pulmonary Rehabilitation for Exercise Tolerance and Quality of Life in IPF Patients: A Systematic Review and Meta-Analysis. BioMed research international. 2019. 31016200
- [7] Di Mauro S, Scamporrino A et al.. Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis. International journal of molecular sciences. 2020 Nov 20. 33233868
- [8] Raghu G, Martinez FJ et al.. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. The European respiratory journal. 2015 Dec. 26493793
- [9] Song JW, Hong SB et al.. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. The European respiratory journal. 2011 Feb. 20595144
- [10] Proesmans VLJ, Drent M et al.. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients. Lung. 2019 Oct. 31440832
- [11] Collard HR, Brown KK et al.. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest. 2014 Nov. 25144827
- [12] Oda K, Yatera K et al.. Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis. Respiratory investigation. 2018 Jan. 29325684
- [13] Vongvivitpatana TS, Nambiar AM. A Low Forced Vital Capacity (FVC)/Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Ratio Increases Clinical Suspicion for Fibrotic Hypersensitivity Pneumonitis (FHP) Over Idiopathic Pulmonary Fibrosis (IPF). Cureus. 2024 Nov. 39634966
- [14] Mari PV, Coppola A et al.. The Impact of Corticosteroids on Mortality in Acute Exacerbations of Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Advances in respiratory medicine. 2025 Mar 28. 40277510
- [15] Cottin V, Crestani B et al.. Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis. Respiratory medicine and research. 2026 May. 42025256
- [16] Li J, Yu XQ et al.. Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial. Frontiers in pharmacology. 2022. 36386223
- [17] Kim ES, Keating GM. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs. 2015 Feb. 25604027
- [18] Feng X, Zeng W et al.. The Presence of Emphysema in Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer: Impact on Tumor Features, Acute Exacerbation, and Survival. Journal of clinical medicine. 2025 May 30. 40507634
- [19] Bermudo G, Rivera-Ortega P et al.. The benefits of a rapid diagnostic primary care circuit for interstitial lung disease. NPJ primary care respiratory medicine. 2025 Nov 26. 41298492
- [20] Kondoh Y, Taniguchi H et al.. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2010 Jul. 21319592
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
